26 Jul Myrtelle
Mark Hurtt, M.D., Acting Chief Medical Officer
Oct. 11 | 9:45am | Ecolab Life Sciences Ballroom
Myrtelle Inc. is a gene therapy company focused on developing transformative treatments for neurodegenerative diseases. The company has a proprietary platform, intellectual property, and portfolio of programs and technologies supporting innovative gene therapy approaches for neurodegenerative diseases. Myrtelle has an exclusive worldwide licensing agreement with Pfizer Inc. for its lead program in Canavan disease.